Literature DB >> 7400830

Follow-up of patients with differentiated thyroid cancer using serum thyroglobulin measured by an immunoradiometric assay. Comparison with I-131 total body scans.

I R McDougall, M F Bayer.   

Abstract

An immunoradiometric assay for thyroglobulin (Tg), which allows quantification of Tg in the presence of anti- Tg, has been evaluated in patients with differentiated thyroid cancer. All patients had undergone thyroidectomy plus I- 131 ablation. Three separate studies have been conducted. 1. Tg levels were compared with I- 131 whole-body scans made at 48 hr in 22 patient studies. Both tests gave similar results in 19 of the studies, but in three patients the results of the tests were discordant. 2. Tg levels were compared with clinical status in 18 patients who were free of disease; 15 had Tg values < 5 ng/ml, and three had measurable but normal Tg values. Three patients with metastatic disease had measurable Tg, and in two the values were above normal. 3. Sequential Tg measurements were made at intervals of 3 mo in 19 patients on thyroxine. Fifteen of these patients had identical results on two or more occasions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400830

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

Review 1.  Management of thyroglobulin positive/whole-body scan negative: is Tg positive/131I therapy useful?

Authors:  I R McDougall
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

2.  The value of serum thyroglobulin measurement as a marker of cancer recurrence in the follow-up of patients previously treated for differentiated thyroid tumor.

Authors:  E Roti; G Robuschi; R Emanuele; P Bandini; A Russo; P Riva; E Galassi; U P Guerra; A Manfredi; A Bozzetti; A M Guazzi; A Gnudi
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

3.  Immunoreactive thyroglobulin in sera and saliva of patients with various thyroid disorders: role of autoantibodies.

Authors:  A J Van Herle; P D Rosenblit; T L Van Herle; P Van Herle; M Greipel; K Kellett
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.